{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T18:24:57Z","timestamp":1788200697275,"version":"build-2803163510"},"reference-count":55,"publisher":"Oxford University Press (OUP)","issue":"73","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,8,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Screening has been instrumental in reducing the global burden of cervical cancer over the past several decades. However, the landscape of prevention and early detection is rapidly evolving, driven by widespread human papillomavirus (HPV) vaccination, advances in molecular diagnostics, and a growing emphasis on personalized medicine, which collectively call for a reassessment of traditional screening paradigms to align with the new risk landscape. In settings with a high prevalence of cervical precancerous lesions, where cytology and HPV testing yield a substantial proportion of true positives, frequent screening intervals are justified. Conversely, in vaccinated populations where the incidence of precancerous lesions is becoming substantially reduced, screening, irrespective of test modality, produces more false positives, leading to unnecessary diagnostic procedures and their consequent reproductive health risks and psychological distress. In HPV-based screening, reduced positive predictive value (PPV) in vaccinated populations reflects the lower oncogenic potential of nonvaccine HPV types that predominate postvaccination. Although these infections are detectable, they are less likely to progress to high-grade precancer or cancer, thereby lowering PPVs. In cytology-based screening, PPV declines for 2 reasons. First, as vaccine-targeted high-risk infections are eliminated, lower-risk infections account for a greater share of cytologic abnormalities. Second, as true precancerous lesions decline, nonspecific cytologic abnormalities, unrelated to HPV, become more prominent, increasing false positives and further reducing PPV. This commentary, drawing on prior work from our group, examines the complex interplay among disease prevalence, individual risk profiles, test performance, and screening program design and argues for a transition toward risk-based screening strategies that reflect changing epidemiological patterns and align with contemporary public health priorities. It further argues for adaptive, evidence-informed policies that incorporate molecular tools such as HPV genotyping and methylation assays to optimize prevention and early detection in the postvaccination era.<\/jats:p>","DOI":"10.1093\/jncimonographs\/lgag007","type":"journal-article","created":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T12:42:36Z","timestamp":1773924156000},"page":"118-125","source":"Crossref","is-referenced-by-count":1,"title":["The need to change cervical cancer screening in the post\u2013human papillomavirus vaccination era: the interplay between disease prevalence and risk, test characteristics, and efficiency of screening programs"],"prefix":"10.1093","volume":"2026","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5190-0370","authenticated-orcid":false,"given":"Mariam","family":"El-Zein","sequence":"first","affiliation":[{"name":"Division of Cancer Epidemiology, McGill University , Montr\u00e9al, QC H4A 3T2,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4409-8084","authenticated-orcid":false,"given":"Eduardo L","family":"Franco","sequence":"additional","affiliation":[{"name":"Division of Cancer Epidemiology, McGill University , Montr\u00e9al, QC H4A 3T2,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,8,31]]},"reference":[{"key":"2026083104013767800_lgag007-B1","doi-asserted-by":"publisher","first-page":"2765","DOI":"10.1002\/cncr.34899","article-title":"The time has come to implement primary human papillomavirus screening for cervical cancer in the United States","volume":"129","author":"Franco","year":"2023","journal-title":"Cancer"},{"key":"2026083104013767800_lgag007-B2","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1080\/14737159.2025.2486653","article-title":"Evolution and future of cervical cancer screening: from cytology to primary HPV testing and the impact of vaccination","volume":"25","author":"El-Zein","year":"2025","journal-title":"Expert Rev Mol Diagn"},{"key":"2026083104013767800_lgag007-B3","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/S0140-6736(19)30298-3","article-title":"Population-level impact and herd effects following the introduction of human papillomavirus vaccination programmes: updated systematic review and meta-analysis","volume":"394","author":"Drolet","year":"2019","journal-title":"Lancet"},{"key":"2026083104013767800_lgag007-B4","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1159\/000528964","article-title":"The future role of cytology in cervical cancer screening in the era of HPV vaccination","volume":"67","author":"Barroeta","year":"2023","journal-title":"Acta Cytol"},{"key":"2026083104013767800_lgag007-B5","doi-asserted-by":"publisher","first-page":"e0140322","DOI":"10.1128\/jcm.01403-22","article-title":"Testing for human papillomaviruses in urine, blood, and oral specimens: an update for the laboratory","volume":"61","author":"Poljak","year":"2023","journal-title":"J Clin Microbiol"},{"key":"2026083104013767800_lgag007-B6","doi-asserted-by":"publisher","first-page":"S3\/171","DOI":"10.1016\/j.vaccine.2006.05.061","article-title":"Chapter 20: issues in planning cervical cancer screening in the era of HPV vaccination","volume":"24(Suppl 3)","author":"Franco","year":"2006","journal-title":"Vaccine"},{"key":"2026083104013767800_lgag007-B7","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1016\/j.arcmed.2009.06.003","article-title":"The expected impact of HPV vaccination on the accuracy of cervical cancer screening: the need for a paradigm change","volume":"40","author":"Franco","year":"2009","journal-title":"Arch Med Res"},{"key":"2026083104013767800_lgag007-B8","doi-asserted-by":"publisher","first-page":"S62","DOI":"10.1016\/j.jcv.2015.11.020","article-title":"Cervical cancer screening of HPV vaccinated populations: cytology, molecular testing, both or none","volume":"76(Suppl 1)","author":"El-Zein","year":"2016","journal-title":"J Clin Virol"},{"key":"2026083104013767800_lgag007-B9","author":"World Health Organization"},{"key":"2026083104013767800_lgag007-B10","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1002\/ijc.21955","article-title":"Overview of the European and North American studies on HPV testing in primary cervical cancer screening","volume":"119","author":"Cuzick","year":"2006","journal-title":"Int J Cancer"},{"key":"2026083104013767800_lgag007-B11","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.2217\/fon.10.141","article-title":"Integrating novel primary- and secondary-prevention strategies: the next challenge for cervical cancer control","volume":"6","author":"Mayrand","year":"2010","journal-title":"Future Oncol"},{"key":"2026083104013767800_lgag007-B12","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1016\/j.path.2018.05.001","article-title":"Updates in cervical cytology: the 90-year-long journey from Battle Creek to today","volume":"11","author":"Roe","year":"2018","journal-title":"Surg Pathol Clin"},{"key":"2026083104013767800_lgag007-B13","doi-asserted-by":"publisher","first-page":"e58","DOI":"10.1017\/S0266462324000540","article-title":"Systematic review of economic evaluations of triage tests for women with atypical squamous cells of undetermined significance (ASC-US) or low-grade squamous intraepithelial lesions (LSIL)","volume":"40","author":"Meirelles","year":"2024","journal-title":"Int J Technol Assess Health Care"},{"key":"2026083104013767800_lgag007-B14","doi-asserted-by":"publisher","first-page":"3305","DOI":"10.1002\/ijc.33178","article-title":"Defining benchmarks for tolerable risk thresholds in cancer screening: impact of HPV vaccination on the future of cervical cancer screening","volume":"147","author":"Tota","year":"2020","journal-title":"Int J Cancer"},{"key":"2026083104013767800_lgag007-B15","doi-asserted-by":"publisher","DOI":"10.2807\/1560-7917.ES.2018.23.41.1700737","article-title":"The impact of 10 years of human papillomavirus (HPV) vaccination in Australia: what additional disease burden will a nonavalent vaccine prevent?","volume":"23","author":"Patel","year":"2018","journal-title":"Euro Surveill"},{"key":"2026083104013767800_lgag007-B16","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1056\/NEJMoa1917338","article-title":"HPV vaccination and the risk of invasive cervical cancer","volume":"383","author":"Lei","year":"2020","journal-title":"N Engl J Med"},{"key":"2026083104013767800_lgag007-B17","doi-asserted-by":"publisher","first-page":"2084","DOI":"10.1016\/S0140-6736(21)02178-4","article-title":"The effects of the national HPV vaccination programme in England, UK, on cervical cancer and grade 3 cervical intraepithelial neoplasia incidence: a register-based observational study","volume":"398","author":"Falcaro","year":"2021","journal-title":"Lancet"},{"key":"2026083104013767800_lgag007-B18","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1093\/jnci\/djad263","article-title":"Invasive cervical cancer incidence following bivalent human papillomavirus vaccination: a population-based observational study of age at immunization, dose, and deprivation","volume":"116","author":"Palmer","year":"2024","journal-title":"J Natl Cancer Inst"},{"key":"2026083104013767800_lgag007-B19","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.ygyno.2025.03.008","article-title":"Validating the predicted impact of HPV vaccination on HPV prevalence, cervical lesions, and cervical cancer: a systematic review of population level data and modelling studies","volume":"195","author":"de Bondt","year":"2025","journal-title":"Gynecol Oncol"},{"key":"2026083104013767800_lgag007-B20","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1186\/s12905-022-02043-y","article-title":"Barriers to uptake of cervical cancer screening services in low-and-middle-income countries: a systematic review","volume":"22","author":"Petersen","year":"2022","journal-title":"BMC Womens Health"},{"key":"2026083104013767800_lgag007-B21","doi-asserted-by":"publisher","first-page":"e2300385","DOI":"10.1200\/GO.23.00385","article-title":"Coverage and socioeconomic inequalities in cervical cancer screening in low- and middle-income countries between 2010 and 2019","volume":"10","author":"Abila","year":"2024","journal-title":"JCO Glob Oncol"},{"key":"2026083104013767800_lgag007-B22","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.vaccine.2023.10.062","article-title":"Status of HPV disease and vaccination programmes in LMICs: introduction to special issue","volume":"42(Suppl. 2)","author":"Borda","year":"2024","journal-title":"Vaccine"},{"key":"2026083104013767800_lgag007-B23","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1038\/bjc.2015.474","article-title":"HPV immunisation and cervical screening\u2014confirmation of changed performance of cytology as a screening test in immunised women: a retrospective population-based cohort study","volume":"114","author":"Palmer","year":"2016","journal-title":"Br J Cancer"},{"key":"2026083104013767800_lgag007-B24","doi-asserted-by":"publisher","first-page":"e2214020","DOI":"10.1001\/jamanetworkopen.2022.14020","article-title":"Test performance of cervical cytology among adults with vs without human papillomavirus vaccination","volume":"5","author":"Teoh","year":"2022","journal-title":"JAMA Netw Open"},{"key":"2026083104013767800_lgag007-B25","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1038\/s41416-020-0850-6","article-title":"Impact of HPV vaccination on cervical screening performance: a population-based cohort study","volume":"123","author":"Lei","year":"2020","journal-title":"Br J Cancer"},{"key":"2026083104013767800_lgag007-B26","doi-asserted-by":"publisher","first-page":"101203","DOI":"10.1016\/j.lanepe.2024.101203","article-title":"Impact of a national HPV vaccination programme for preadolescent girls on cytology screening performance and CIN2+ incidence: five-year population-based cervical screening results from Slovenia","volume":"50","author":"Irzaldy","year":"2025","journal-title":"Lancet Reg Health Eur"},{"key":"2026083104013767800_lgag007-B27","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.1007\/s10552-025-02039-7","article-title":"Positive predictive value of cervical cancer screening results recommended for colposcopy by human papillomavirus vaccination status at 3 U.S. healthcare systems","volume":"36","author":"Pocobelli","year":"2025","journal-title":"Cancer Causes Control"},{"key":"2026083104013767800_lgag007-B28","doi-asserted-by":"publisher","first-page":"311","DOI":"10.3949\/ccjm.62.5.311","article-title":"Accuracy and predictive values in clinical decision-making","volume":"62","author":"Eisenberg","year":"1995","journal-title":"Cleve Clin J Med"},{"key":"2026083104013767800_lgag007-B29","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1136\/sextrans-2019-054290","article-title":"Levels of anxiety and distress following receipt of positive screening tests in Australia\u2019s HPV-based cervical screening programme: a cross-sectional survey","volume":"96","author":"Dodd","year":"2020","journal-title":"Sex Transm Infect"},{"key":"2026083104013767800_lgag007-B30","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1080\/17501911.2024.2402684","article-title":"Will methylation assays be part of a full molecular strategy to improve clinical management of cervical neoplasia?","volume":"16","author":"El-Zein","year":"2024","journal-title":"Epigenomics"},{"key":"2026083104013767800_lgag007-B31","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1186\/s13148-023-01537-2","article-title":"DNA methylation as a triage marker for colposcopy referral in HPV-based cervical cancer screening: a systematic review and meta-analysis","volume":"15","author":"Salta","year":"2023","journal-title":"Clin Epigenetics"},{"key":"2026083104013767800_lgag007-B32","doi-asserted-by":"publisher","first-page":"2582","DOI":"10.1093\/cid\/ciz677","article-title":"Methylation in predicting progression of untreated high-grade cervical intraepithelial neoplasia","volume":"70","author":"Louvanto","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2026083104013767800_lgag007-B33","doi-asserted-by":"publisher","first-page":"3037","DOI":"10.1200\/JCO.21.02433","article-title":"Clinical regression of high-grade cervical intraepithelial neoplasia is associated with absence of FAM19A4\/miR124-2 DNA methylation (CONCERVE study)","volume":"40","author":"Kremer","year":"2022","journal-title":"J Clin Oncol"},{"key":"2026083104013767800_lgag007-B34","doi-asserted-by":"publisher","first-page":"1781","DOI":"10.1111\/aogs.14915","article-title":"Clinical performance of human papillomavirus based cervical cancer screening algorithm: the result of a large Danish implementation study","volume":"103","author":"Lindquist","year":"2024","journal-title":"Acta Obstet Gynecol Scand"},{"key":"2026083104013767800_lgag007-B35","doi-asserted-by":"publisher","first-page":"102438","DOI":"10.1016\/j.pmedr.2023.102438","article-title":"Acceptability of deferring the start of cervical cancer screening to age 30 for women vaccinated against human papillomavirus","volume":"36","author":"Martello","year":"2023","journal-title":"Prev Med Rep"},{"key":"2026083104013767800_lgag007-B36","doi-asserted-by":"publisher","first-page":"e1004505","DOI":"10.1371\/journal.pmed.1004505","article-title":"Evaluation of primary HPV-based cervical screening among older women: long-term follow-up of a randomized healthcare policy trial in Sweden","volume":"21","author":"Yao","year":"2024","journal-title":"PLoS Med"},{"key":"2026083104013767800_lgag007-B37","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1002\/ijc.35142","article-title":"Nationwide registry-based trial of risk-stratified cervical screening","volume":"156","author":"Arroyo Muhr","year":"2025","journal-title":"Int J Cancer"},{"key":"2026083104013767800_lgag007-B38","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.ypmed.2016.12.028","article-title":"Cervical cancer screening: epidemiology as the necessary but not sufficient basis of public health practice","volume":"98","author":"Schiffman","year":"2017","journal-title":"Prev Med"},{"key":"2026083104013767800_lgag007-B39","first-page":"2","author":"Kyrgiou","year":"2016"},{"key":"2026083104013767800_lgag007-B40","doi-asserted-by":"publisher","first-page":"3679","DOI":"10.1038\/s41467-024-47909-x","article-title":"Concomitant human papillomavirus (HPV) vaccination and screening for elimination of HPV and cervical cancer","volume":"15","author":"Arroyo Muhr","year":"2024","journal-title":"Nat Commun"},{"key":"2026083104013767800_lgag007-B41","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.ypmed.2016.11.020","article-title":"Cervical cancer screening in women vaccinated against human papillomavirus infection: recommendations from a consensus conference","volume":"98","author":"Giorgi Rossi","year":"2017","journal-title":"Prev Med"},{"key":"2026083104013767800_lgag007-B42","author":"Cancer IAfRo","year":"2026"},{"key":"2026083104013767800_lgag007-B43","author":"Commission E","year":"2026"},{"key":"2026083104013767800_lgag007-B44","doi-asserted-by":"publisher","first-page":"1314","DOI":"10.1186\/s12885-024-13050-7","article-title":"Women\u2019s perspectives on the acceptability of risk-based cervical cancer screening","volume":"24","author":"Remmel","year":"2024","journal-title":"BMC Cancer"},{"key":"2026083104013767800_lgag007-B45","doi-asserted-by":"publisher","first-page":"106237","DOI":"10.1016\/j.ypmed.2020.106237","article-title":"The role and utility of population-based cancer registries in cervical cancer surveillance and control","volume":"144","author":"Pineros","year":"2021","journal-title":"Prev Med"},{"key":"2026083104013767800_lgag007-B46","doi-asserted-by":"publisher","first-page":"2583577","DOI":"10.1080\/21645515.2025.2583577","article-title":"Effect of human papillomavirus (HPV) vaccine on HPV type replacement and sexual behaviors in the post-vaccine era: a cross-sectional study","volume":"21","author":"Zhang","year":"2025","journal-title":"Hum Vaccin Immunother"},{"key":"2026083104013767800_lgag007-B47","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1016\/S1470-2045(22)00291-1","article-title":"Precancerous cervical lesions caused by non-vaccine-preventable HPV types after vaccination with the bivalent AS04-adjuvanted HPV vaccine: an analysis of the long-term follow-up study from the randomised Costa Rica HPV Vaccine Trial","volume":"23","author":"Shing","year":"2022","journal-title":"Lancet Oncol"},{"key":"2026083104013767800_lgag007-B48","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1002\/ijc.70119","article-title":"Epidemiological approaches to evaluate clinical unmasking of HPV-associated cervical lesions in the HPV vaccination era","volume":"158","author":"Tota","year":"2026","journal-title":"Int J Cancer"},{"key":"2026083104013767800_lgag007-B49","doi-asserted-by":"publisher","first-page":"e886","DOI":"10.1016\/S2468-2667(24)00218-4","article-title":"Human papillomavirus-based cervical screening and long-term cervical cancer risk: a randomised health-care policy trial in Sweden","volume":"9","author":"Wang","year":"2024","journal-title":"Lancet Public Health"},{"key":"2026083104013767800_lgag007-B50","doi-asserted-by":"publisher","first-page":"e068776","DOI":"10.1136\/bmj-2021-068776","article-title":"Extension of cervical screening intervals with primary human papillomavirus testing: observational study of English screening pilot data","volume":"377","author":"Rebolj","year":"2022","journal-title":"BMJ"},{"key":"2026083104013767800_lgag007-B51","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.ygyno.2014.11.076","article-title":"Primary cervical cancer screening with human papillomavirus: end of study results from the ATHENA study using HPV as the first-line screening test","volume":"136","author":"Wright","year":"2015","journal-title":"Gynecol Oncol"},{"key":"2026083104013767800_lgag007-B52","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.3747\/co.25.3969","article-title":"Self-sampling for cervical cancer screening: empowering women to lead a paradigm change in cancer control","volume":"25","author":"Franco","year":"2018","journal-title":"Curr Oncol"},{"key":"2026083104013767800_lgag007-B53","doi-asserted-by":"publisher","first-page":"1567509","DOI":"10.3389\/fmed.2025.1567509","article-title":"Assessment of HPV screening modalities within primary care: a systematic review","volume":"12","author":"Waly","year":"2025","journal-title":"Front Med (Lausanne)"},{"key":"2026083104013767800_lgag007-B54","doi-asserted-by":"publisher","first-page":"3050","DOI":"10.1038\/s41591-023-02600-4","article-title":"Benefits, harms and cost-effectiveness of cervical screening, triage and treatment strategies for women in the general population","volume":"29","author":"Simms","year":"2023","journal-title":"Nat Med"},{"key":"2026083104013767800_lgag007-B55","doi-asserted-by":"publisher","first-page":"1733","DOI":"10.1038\/s41416-024-02681-z","article-title":"Predictable changes in the accuracy of human papillomavirus tests after vaccination: review with implications for performance monitoring in cervical screening","volume":"130","author":"Rebolj","year":"2024","journal-title":"Br J Cancer"}],"container-title":["JNCI Monographs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jncimono\/article-pdf\/2026\/73\/118\/70870252\/lgag007.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jncimono\/article-pdf\/2026\/73\/118\/70870252\/lgag007.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T08:01:44Z","timestamp":1788163304000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jncimono\/article\/2026\/73\/118\/8776086"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,1]]},"references-count":55,"journal-issue":{"issue":"73","published-online":{"date-parts":[[2026,8,31]]},"published-print":{"date-parts":[[2026,8,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jncimonographs\/lgag007","relation":{},"ISSN":["1052-6773","1745-6614"],"issn-type":[{"value":"1052-6773","type":"print"},{"value":"1745-6614","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,8]]},"published":{"date-parts":[[2026,8,1]]}}}